Aerovate Therapeutics enters into $75M ATM equity offering with BofA Securities

Jade Biosciences, Inc.

Entered into ATM Sales Agreement with BofA Securities to sell up to $75M of common stock.
Shares sold at market prices; BofA receives 3% commission on gross proceeds.
Company not obligated to sell any shares; may suspend or terminate offering at any time.
Offering made under existing effective shelf registration statement on Form S-3.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Jade Biosciences, Inc. entered into ATM Equity Offering SM Sales Agreement with BofA Securities, Inc. valued at up to $75,000,000 (effective 2023-04-05).

Action: entry
Agreement: atm program
Counterparty: BofA Securities, Inc.
Value: up to $75,000,000
Effective: 2023-04-05

Exact text from the filing

On April 5, 2023, Aerovate Therapeutics, Inc. (the “Company”) entered into an ATM Equity Offering SM Sales Agreement (the “Sales Agreement”), with BofA Securities, Inc. (“BofA”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $75,000,000 (the “Shares”) through BofA as its sales agent or to BofA as principal for its own account.

View on SEC.gov

37 material agreements filed in the last 30 days. Browse all material agreements →

Jade Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001798749-23-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.